JRS Pharma, a leading manufacturer of excipients, in partnership with Gujarat Microwax Pvt Ltd., has commissioned a new manufacturing facility for cotton-based croscarmellose sodium. This state-of-the-art plant, which opened on July 10, 2024, is located in Mehsana and marks their fourth manufacturing facility in India. The grand opening ceremony was attended by heads of over 50 prominent pharmaceutical companies in the region, among other dignitaries.

JRS Pharma, known for its plant fibre technology innovations and with a legacy of 149 years, offers a comprehensive portfolio of solutions for the global health science industry. Their excipients portfolio includes high functionality excipients, binders, disintegrants, lubricants, functional fillers, thickeners, stabilizers, carriers, and coatings. JRS Pharma and Gujarat Microwax Pvt Ltd. have enjoyed a successful 18-year partnership. Speaking at the grand opening, Rohit Raut, Managing Director, Rettenmaier India, the Indian subsidiary of JRS Group, said, "The excipients market in India is growing due to rising awareness of health and wellness, increasing disposable incomes, and an aging population. Our new facility will cater to the fast-growing demand for functional excipients in India."

Manas Jhajharia, Director, Gujarat Microwax Pvt Ltd., emphasised, "The Indian excipient industry, with less than 1% market share globally, needs quality improvement to reduce dependency on imports. Our Mehsana plant operations have a world-class production facility that meets global standards for the export of quality excipients."

Alongside their extensive range of excipients, JRS Pharma also offers excellent technical support and biopharma services to address customer needs and formulation challenges. This expansion marks a significant step towards self-sufficiency in the Indian excipient industry.

(Source: PTI)